🇺🇸 FDA

Intelligence · Clinical Pipeline

Takeda Pipeline

All ClinicalTrials.gov programs at Takeda — phase, modality, and trial IDs.

Programs
1,179

Quick answer

Takeda has 1,179 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. TAK-418

    Takeda

    Healthy Participants

    phase 1 small molecule completed

    1 trial

  2. TAK-418

    Takeda

    Healthy Volunteers

    phase 1 small molecule terminated

    2 trials

  3. TAK-438

    Takeda

    Dose Finding Study

    phase 1 small molecule completed

    2 trials

  4. TAK-438

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  5. TAK-438

    Takeda

    Healthy Participants

    phase 1 small molecule completed

    1 trial

  6. TAK-438

    Takeda

    Erosive Esophagitis(EE)

    phase 1 small molecule completed

    1 trial

  7. TAK-438

    Takeda

    Ascending Single Dose Study

    phase 1 small molecule completed

    1 trial

  8. TAK-438 OD

    Takeda

    Japanese Healthy Adult Male

    phase 1 small molecule completed

    1 trial

  9. TAK-438ASA

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  10. TAK-491

    Takeda

    Healthy Volunteer

    phase 1 small molecule completed

    1 trial

  11. TAK-510

    Takeda

    Healthy Participants

    phase 1 small molecule completed

    1 trial

  12. TAK-536

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  13. TAK-536

    Takeda

    Japanese Healthy Adult Male Participants

    phase 1 small molecule completed

    1 trial

  14. TAK-536 Tablet

    Takeda

    Japanese Healthy Adult Males

    phase 1 small molecule completed

    1 trial

  15. TAK-536TCH

    Takeda

    Hypertension

    phase 1 small molecule completed

    1 trial

  16. TAK-580

    Takeda

    Melanoma

    phase 1 small molecule terminated

    1 trial

  17. TAK-648

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  18. TAK-648

    Takeda

    Type 2 Diabetes Mellitus

    phase 1 small molecule completed

    1 trial

  19. TAK-648 Tablet

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  20. TAK-659

    Takeda

    Lymphoma, Non-Hodgkin

    phase 1 small molecule terminated

    1 trial

  21. TAK-671

    Takeda

    Coronavirus Disease

    phase 1 small molecule terminated

    1 trial

  22. TAK-676

    Takeda

    Head and Neck Squamous Cell Carcinoma

    phase 1 small molecule completed

    1 trial

  23. TAK-755

    Takeda

    Sickle Cell Disease

    phase 1 small molecule completed

    1 trial

  24. TAK-781

    Takeda

    Healthy Volunteers

    phase 1 small molecule active

    1 trial

  25. TAK-788

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    3 trials

  26. TAK-792 30 mg

    Takeda

    Healthy Male Adults Participants

    phase 1 small molecule completed

    1 trial

  27. TAK-828

    Takeda

    Healthy Volunteers

    phase 1 small molecule terminated

    1 trial

  28. TAK-828

    Takeda

    Dose Finding Study

    phase 1 small molecule completed

    1 trial

  29. TAK-861, TAK-861, TAK-861

    Takeda

    Narcolepsy with Cataplexy (Narcolepsy Type 1)

    phase 1 small molecule active

    1 trial

  30. TAK-875 and Glimepiride

    Takeda

    Pharmacokinetics

    phase 1 small molecule completed

    1 trial

  31. TAK-881

    Takeda

    Healthy Volunteers

    phase 1 mab completed

    3 trials

  32. TAK-906

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    3 trials

  33. TAK-906

    Takeda

    Japanese Healthy Adult Male Participants

    phase 1 small molecule completed

    1 trial

  34. TAK-906 Maleate

    Takeda

    Healthy Participants

    phase 1 small molecule completed

    1 trial

  35. TAK-906 Oral Capsule

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  36. TAK-915

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  37. TAK-915 suspension

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  38. TAK-925

    Takeda

    Healthy Participants

    phase 1 small molecule completed

    1 trial

  39. TAK-925

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  40. TAK-925

    Takeda

    Obstructive Sleep Apnea

    phase 1 small molecule completed

    1 trial

  41. TAK-925

    Takeda

    Healthy Participants and Patients With Narcolepsy

    phase 1 small molecule completed

    1 trial

  42. TAK-925

    Takeda

    Idiopathic Hypersomnia

    phase 1 small molecule completed

    1 trial

  43. TAK-931

    Takeda

    Nonhematologic Neoplasms, Advanced

    phase 1 small molecule completed

    1 trial

  44. TAK-931 PIC

    Takeda

    Neoplasms, Advanced Solid

    phase 1 small molecule completed

    1 trial

  45. TAK-935

    Takeda

    Epilepsy, Molecular Mechanisms of Pharmalogical Action, Protective Agents

    phase 1 small molecule completed

    1 trial

  46. TAK-935

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  47. TAK-935

    Takeda

    Healthy Volunteer

    phase 1 small molecule completed

    1 trial

  48. TAK-935 Oral Tablet

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many pipeline programs does Takeda have?

1,179 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.